Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis

Neurotherapeutics. 2016 Jan;13(1):47-57. doi: 10.1007/s13311-015-0412-4.

Abstract

Treatment options in relapsing-remitting multiple sclerosis have increased considerably in recent years; currently, a dozen different preparations of disease-modifying therapies are available and some more are expected to be marketed soon. For the treating neurologist this broad therapeutic repertoire not only greatly improves individualized management of the disease, but also makes choices more complex and difficult. A number of factors must be considered, including disease activity and severity, safety profile, and patient preference. We here discuss the currently existing options and suggest treatment algorithms for managing relapsing-remitting multiple sclerosis.

Keywords: Disease-modifying therapy; Relapsing-remitting multiple sclerosis; Treatment algorithm; Treatment decisions.

Publication types

  • Review

MeSH terms

  • Alemtuzumab
  • Algorithms
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Crotonates / therapeutic use
  • Dimethyl Fumarate / therapeutic use
  • Fingolimod Hydrochloride / therapeutic use
  • Glatiramer Acetate / therapeutic use
  • Humans
  • Hydroxybutyrates
  • Interferon-beta / therapeutic use
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Natalizumab / therapeutic use
  • Nitriles
  • Toluidines / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Crotonates
  • Hydroxybutyrates
  • Natalizumab
  • Nitriles
  • Toluidines
  • teriflunomide
  • Alemtuzumab
  • Glatiramer Acetate
  • Interferon-beta
  • Dimethyl Fumarate
  • Fingolimod Hydrochloride